Actuarial Drivers: Unlocking Multi-Year RPM Savings for Investors

The field of value-based care is rapidly evolving, and with it, the scrutiny applied to the economic claims of digital health platforms. Short-term pilot programs, once sufficient to initiate payer discussions, are increasingly viewed with skepticism by actuaries, value-based care investors, and health plan benefit designers. The critical question has shifted from “Does it work?” to “Does it drive multi-year, actuarially sound savings?” This demands a deeper analysis of sustained patient engagement, clinical outcomes, and, importantly, risk-adjusted total cost of care reduction over extended periods.

Beyond the Pilot: Why Multi-Year Actuarial Value is Paramount

The initial enthusiasm for remote patient monitoring (RPM) platforms often stemmed from promising early results, demonstrating improvements in specific biometric markers or short-term reductions in acute events. However, these pilots frequently fail to capture the true economic drivers that dictate long-term value in value-based care arrangements. The challenge lies in proving that these interventions lead to sustained behavioral change, prevent disease progression, and in the end bend the cost curve over several benefit cycles. For actuaries, the focus is on the predictability and durability of savings. A platform might show impressive engagement in the first six months, but if that engagement wanes, or if the initial health improvements are not maintained, the actuarial model for multi-year savings collapses. Investors, too, are now looking past headline-grabbing initial reductions, demanding evidence of a “data moat” built on proprietary, long-term outcomes data that demonstrates enduring financial performance. Health plan benefit designers, tasked with allocating precious resources, require clear evidence that a digital health solution will yield a positive return on investment (ROI) over the entire contract term, not just in the initial implementation phase.

Evidence of Multi-Year Savings Curves: Lessons from Omada and Livongo

While many platforms struggle to provide strong, peer-reviewed evidence of long-term financial impact, some have begun to meet this heightened standard. Platforms like Omada Health and Livongo (now part of Teladoc Health) have been at the forefront of demonstrating multi-year savings through rigorous analysis and peer-reviewed publications. Omada Health, known for its clinically validated virtual care programs, has published studies showing sustained reductions in healthcare costs for individuals enrolled in their digital diabetes prevention and management programs. These studies often track participants for two to three years, demonstrating not only initial weight loss and A1c reductions but also a sustained decrease in utilization of high-cost services such as emergency department visits and inpatient admissions. For example, recent peer-reviewed research published in April 2026 demonstrated significant net PMPM savings in musculoskeletal condition-related total costs and physical therapy costs at 6 and 12 months for patients using Omada’s virtual physical therapy program. The key actuarial driver here is the sustained engagement that translates into a reduced incidence of diabetes complications, which are significant cost drivers. Omada Health peer-reviewed cost savings study Livongo, a pioneer in remote diabetes monitoring, similarly built its reputation on outcomes data. Before its acquisition by Teladoc Health, Livongo consistently published peer-reviewed figures detailing per member per month (PMPM) savings. For instance, a 2018 study showed a 1.4x ROI in Year 1 with $70 PPPM cost savings for participants in Livongo’s diabetes program, including a 35% decrease in diabetes-related medical spending. Their research highlighted how continuous glucose monitoring, coupled with AI-driven personalized coaching and interventions, led to improved glycemic control and a reduction in medical claims costs over multiple years. The strength of Livongo’s approach lay in its ability to demonstrate high retention rates and multi-year engagement curves, which are critical for actuaries modeling long-term cost avoidance. These platforms illustrate that meaningful cost reduction is not a one-time event but a cumulative effect of sustained behavioral modification and proactive chronic disease management. The strategic acquisition of Livongo by Teladoc Health underscored the market’s recognition of platforms that can deliver verifiable, long-term financial performance. Teladoc Health’s expanded virtual care suite now benefits from Livongo’s established track record of demonstrating outcomes-based AI health financial performance, an important differentiator in a crowded market. Teladoc Health continues to report strong engagement and clinical outcomes, with data from 2023 showing 75% of Primary360 members remaining engaged at 12 months and a 19% reduction in emergency department visits for a large health plan client.

Actuarial Metrics Investors Must Demand from Chronic Disease Management Platforms

For actuaries, value-based care investors, and health plan benefit designers, evaluating chronic disease management platforms requires a move beyond superficial metrics. The following actuarial drivers and data points are essential for assessing multi-year savings potential:

• Peer-Reviewed PMPM Savings Figures: Demand studies published in reputable journals that quantify PMPM savings, ideally adjusted for risk and comorbidities. These figures should extend beyond a single year to demonstrate durability.
• Retention Rates and Multi-Year Engagement Curves: High initial engagement means little if participants drop off after a few months. Platforms must provide data on sustained engagement, demonstrating how their AI-driven interventions maintain user participation over 24-36 months or more. This includes metrics like app usage frequency, completion rates of program modules, and ongoing biometric data submission.
• Risk-Adjusted Total Cost of Care (TCOC) Reduction: The gold standard is evidence of TCOC reduction, not just savings in a siloed area. This requires strong claims analysis, controlling for baseline health status, demographic factors, and other potential confounding variables. Platforms should be able to demonstrate how their intervention impacts overall healthcare utilization across the continuum of care.
• Clinical Outcome Markers with Sustained Impact: Beyond cost, platforms must demonstrate sustained improvement in relevant clinical markers (e.g., A1c, blood pressure, weight, LDL-C) that are directly linked to reduced disease progression and complications. These improvements should be maintained over the long term.
• NCQA Digital Quality Measures Adherence: The National Committee for Quality Assurance (NCQA) establishes rigorous quality standards. NCQA is actively transitioning to FHIR-based digital quality measures, and platforms demonstrating adherence to these evolving standards provide an additional layer of assurance regarding the quality and effectiveness of their interventions. NCQA digital quality measures guidance
• Evidence of Algorithmic Drift Monitoring: For AI-driven platforms, understanding how they monitor and mitigate algorithmic drift is important. As real-world data distributions shift, the performance of an AI model can degrade. Investors should inquire about the platform’s “PCCP” (Predetermined Change Control Plan) if applicable, or their strategy for continuous model validation and retraining to ensure sustained efficacy.
• Strong Data Security and Compliance: Given the sensitive nature of health data, platforms must demonstrate adherence to HIPAA, HITRUST, or SOC 2 Type II certifications. HITRUST, for example, offers various levels of certification (e1, i1, r2) with the r2 assessment being the most rigorous and widely recognized in healthcare for its complete risk-based approach. This is a foundational element of trust and operational integrity, signaling a mature company. HITRUST certification requirements

Methodology and Source Note

Our analysis emphasizes the critical need for peer-reviewed cost-reduction datasets and adherence to established quality standards like those from NCQA. The insights presented are derived from an actuarial and economic analysis of published research, focusing on the long-term ROI of remote patient monitoring. While this article references companies like Omada Health and Livongo for their demonstrated ability to publish strong outcomes data, it is important for investors and health plans to conduct their own thorough due diligence, demanding similar levels of evidence from any chronic disease management platform. The era of short-term promises is over. Value-based care demands verifiable, multi-year actuarial value.